Prostate Cancer, Hereditary, 8 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HPC8 MCID: PRS130 MIFTS: 41	Prostate Cancer, Hereditary, 8 (HPC8) Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Prostate Cancer, Hereditary, 8

MalaCards integrated aliases for Prostate Cancer, Hereditary, 8:

Name: Prostate Cancer, Hereditary, 8 ⁵⁷

Predisposing for Prostate Cancer ⁵⁷ ¹²

Prostate Cancer, Susceptibility to ⁵⁷

Prostate Cancer ⁵⁷

Hpc8 ⁵⁷

Pcap ⁵⁷

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 602759

MedGen ⁴⁰ C1864472

Sources

Summaries for Prostate Cancer, Hereditary, 8

MalaCards based summary: Prostate Cancer, Hereditary, 8, also known as predisposing for prostate cancer, is related to prostate cancer and prostate cancer, hereditary, 6. An important gene associated with Prostate Cancer, Hereditary, 8 is PCAP (Predisposing For Prostate Cancer). The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and bone.

More information from OMIM: 602759

Sources

Related Diseases for Prostate Cancer, Hereditary, 8

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1	Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3	Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5	Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7	Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10	Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13	Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14	Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2	Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1613)

#	Related Disease	Score
1	prostate cancer	12.4
2	prostate cancer, hereditary, 6	12.1
3	prostate cancer, hereditary, 1	11.7
4	prostate cancer, hereditary, 2	11.7
5	prostate cancer, hereditary, 4	11.7
6	prostate cancer, hereditary, 13	11.6
7	prostate cancer, hereditary, 12	11.6
8	prostate cancer, hereditary, 11	11.6
9	prostate cancer, hereditary, 7	11.5
10	pachyonychia congenita 3	11.5
11	prostate disease	11.5
12	prostate cancer, hereditary, 3	11.5
13	prostate cancer, hereditary, 9	11.5
14	prostate cancer/brain cancer susceptibility	11.5
15	prostate cancer, hereditary, x-linked 1	11.4
16	prostatic hyperplasia, benign	11.4
17	prostate cancer, hereditary, 10	11.4
18	prostate cancer, hereditary, 15	11.3
19	prostate cancer, hereditary, 14	11.3
20	prostate cancer, hereditary, x-linked 2	11.3
21	prostate cancer, hereditary, 5	11.3
22	suppression of tumorigenicity 12	11.2
23	breast cancer	11.2
24	impotence	11.2
25	diethylstilbestrol syndrome	11.2
26	radiation proctitis	11.2
27	alopecia, androgenetic, 1	11.1
28	tatton-brown-rahman syndrome	11.1
29	prostate cancer aggressiveness quantitative trait locus on chromosome 19	11.1
30	breast-ovarian cancer, familial 1	11.1
31	adenocarcinoma	11.1
32	prostate sarcoma	11.0
33	diffuse gastric and lobular breast cancer syndrome	11.0
34	prostate lymphoma	11.0
35	intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies	11.0
36	prostate malignant phyllodes tumor	11.0
37	rhabdomyosarcoma 2	11.0
38	severe combined immunodeficiency	11.0
39	neutropenia	11.0
40	prostatitis	11.0
41	factor vii deficiency	11.0
42	rickets	11.0
43	ceroid lipofuscinosis, neuronal, 5	10.9
44	pure red-cell aplasia	10.9
45	bladder cancer	10.9
46	bone disease	10.9
47	49, xxxxy syndrome	10.9
48	neurodegeneration with brain iron accumulation 2a	10.9
49	proctitis	10.9
50	47 xxx syndrome	10.8

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 8:

Sources

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 8

Clinical features from OMIM®:

602759 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Prostate Cancer, Hereditary, 8

Drugs for Prostate Cancer, Hereditary, 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 833)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Udenafil

Approved, Investigational

Phase 4

268203-93-6

6918523 135413547

Zoledronic acid

Approved

Phase 4

118072-93-8

68740

Finasteride

Approved

Phase 4

98319-26-7

57363

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Lenograstim

Approved, Investigational

Phase 4

135968-09-1

Ranitidine

Approved, Withdrawn

Phase 4

66357-59-3, 82530-72-1, 66357-35-5

3001055 5039

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1, 93107-08-5

2764

Acetaminophen

Approved

Phase 4

103-90-2

1983

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Granisetron

Approved, Investigational

Phase 4

109889-09-0

3510 5284566

Risedronic acid

Approved, Investigational

Phase 4

105462-24-6

5245

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Etidronic acid

Approved

Phase 4

2809-21-4, 7414-83-7

3305

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Desflurane

Approved

Phase 4

57041-67-5

42113

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Hydromorphone

Approved, Illicit

Phase 4

466-99-9, 71-68-1

5284570

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Icodextrin

Approved, Investigational

Phase 4

337376-15-5

Clavulanic acid

Approved, Vet_approved

Phase 4

58001-44-8

5280980

Fosfomycin

Approved

Phase 4

23155-02-4

446987

Denosumab

Approved

Phase 4

615258-40-7

Pamidronic acid

Approved

Phase 4

40391-99-9

4674

Naproxen

Approved, Vet_approved

Phase 4

22204-53-1

156391 1302

Ibuprofen

Approved

Phase 4

15687-27-1

3672

Pasireotide

Approved

Phase 4

396091-73-9

56841596 9941444

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Cabergoline

Approved

Phase 4

81409-90-7

54746

Abarelix

Approved, Investigational, Withdrawn

Phase 4

183552-38-7

21879626 16131215

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Dexchlorpheniramine

Experimental, Investigational

Phase 4

25523-97-1

33036

Amdinocillin

Investigational, Withdrawn

Phase 4

32887-01-7

36273

Phosphodiesterase Inhibitors

Phase 4

Gastrointestinal Agents

Phase 4

Diphosphonates

Phase 4

Anesthetics

Phase 4

5-alpha Reductase Inhibitors

Phase 4

Folic Acid Antagonists

Phase 4

Anti-Ulcer Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 5255)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer	Unknown status	NCT02757365	Phase 4	aspirin;Levofloxacin
2	A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix	Unknown status	NCT03202381	Phase 4	Degarelix
3	MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer?	Unknown status	NCT00185029	Phase 4
4	METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer	Unknown status	NCT02511665	Phase 4	Metformin;Placebo
5	Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer	Unknown status	NCT00293670	Phase 4	Goserelin (Zoladex)
6	Prospective Evaluation of Truebeam STX Stereotactic Body Radiosurgery for Low and Intermediate Risk Prostate Cancer	Unknown status	NCT01581749	Phase 4
7	Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer	Unknown status	NCT01379742	Phase 4
8	A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy	Unknown status	NCT03142542	Phase 4	ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
9	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer	Completed	NCT00219271	Phase 4	Zoledronic acid
10	A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase	Completed	NCT00470834	Phase 4	dutasteride;placebo;bicalutamide
11	A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer	Completed	NCT00375765	Phase 4	Dutasteride
12	A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure	Completed	NCT01977651	Phase 4	Enzalutamide
13	The Prognosis of Lipid Reprogramming With the HMG-CoA Reductase Inhibitor, Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients	Completed	NCT04776889	Phase 4	Rosuvastatin 20mg
14	A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study	Completed	NCT02721433	Phase 4	Pamidronate;Denosumab;Zoledronate
15	A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate	Completed	NCT02116582	Phase 4	Enzalutamide
16	A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CONTINUED ENZALUTAMIDE TREATMENT BEYOND PROGRESSION IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	Completed	NCT01995513	Phase 4	Enzalutamide;Abiraterone;Placebo for Enzalutamide;Prednisone
17	A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)	Completed	NCT03035032	Phase 4	Leuprolide
18	A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety	Completed	NCT00434447	Phase 4	Zoledronic acid
19	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer	Completed	NCT00391690	Phase 4	Zoledronic acid
20	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin	Completed	NCT02102646	Phase 4	Triptorelin
21	An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer	Completed	NCT02726009	Phase 4	Degarelix
22	Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy	Completed	NCT00805701	Phase 4	avodart;Placebo
23	Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen	Completed	NCT02074137	Phase 4	CABAZITAXEL XRP6258;Prednisone;Prednisolone
24	A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer	Completed	NCT00434317	Phase 4	Zoledronic acid
25	A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates	Completed	NCT00172016	Phase 4	Zoledronic acid
26	A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists	Completed	NCT02475057	Phase 4	Degarelix (LHRH antagonist);LHRH agonist
27	Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer	Completed	NCT02441894	Phase 4	CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
28	A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions	Completed	NCT00029224	Phase 4	zoledronic acid
29	An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients	Completed	NCT00590213	Phase 4	Casodex 150mg
30	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer	Completed	NCT00199485	Phase 4	Angelica Sinensis
31	A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.	Completed	NCT01649635	Phase 4	CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
32	A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy	Completed	NCT02405858	Phase 4	Abiraterone Acetate;Prednisolone
33	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases	Completed	NCT00242554	Phase 4	Zoledronic acid
34	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.	Completed	NCT00237146	Phase 4	Zoledronic acid
35	A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer	Completed	NCT00220194	Phase 4	leuprolide acetate
36	A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management	Completed	NCT00363311	Phase 4	Dutasteride;Matching placebo
37	A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis	Completed	NCT00334139	Phase 4	Zoledronic Acid
38	Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis	Completed	NCT00237159	Phase 4	Zoledronic acid
39	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases	Completed	NCT00219219	Phase 4	Zoledronic acid
40	Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment	Completed	NCT00280098	Phase 4	docetaxel
41	Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy	Completed	NCT00245518	Phase 4	Isoflavone;Placebos
42	Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis	Completed	NCT00241111	Phase 4	zoledronic acid
43	An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis	Completed	NCT00035997	Phase 4	Zometa
44	PRospective, Multicenter Study to Evaluate Safety and Efficacy of Switching Treatments of Prostate Cancer Patients, Initially on Use of Monthly or Quarterly Goserelin Acetate (Zoladex®), to Semiannually Leuprorelin Acetate (Eligard®)	Completed	NCT05304169	Phase 4	Leuprorelin Acetate (Eligard® 45 mg).
45	A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer	Completed	NCT01136226	Phase 4	Eligard (TM)
46	Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve?	Completed	NCT01230905	Phase 4
47	Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer	Completed	NCT01511874	Phase 4	ELIGARD 22.5mg
48	A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)	Completed	NCT02918968	Phase 4	Enzalutamide;Flutamide
49	A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients	Completed	NCT01753297	Phase 4	Triptorelin 11.25 mg
50	Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer	Completed	NCT01161563	Phase 4	Triptorelin pamoate;Leuprolide acetate

Search NIH Clinical Center for Prostate Cancer, Hereditary, 8

Sources

Genetic Tests for Prostate Cancer, Hereditary, 8

Sources

Anatomical Context for Prostate Cancer, Hereditary, 8

Organs/tissues related to Prostate Cancer, Hereditary, 8:

MalaCards : Prostate, Lymph Node, Bone, Breast, Bone Marrow, T Cells, Lung

Sources

Publications for Prostate Cancer, Hereditary, 8

Articles related to Prostate Cancer, Hereditary, 8:

(show top 50) (show all 30187)

#	Title	Authors	PMID	Year
1	PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. ⁶² ⁵⁷	Cancel-Tassin G...Cussenot O	11313747	2001
2	Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. ⁶² ⁵⁷	Gibbs M...Ostrander EA	10090894	1999
3	Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. ⁶² ⁵⁷	Berthon P...Cussenot O	9585607	1998
4	Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. ⁶² ⁵⁷	Smith JR...Isaacs WB	8910276	1996
5	Prostate cancer aggressiveness and financial toxicity among prostate cancer patients. ⁶²	Kc M...Peters ES	36063402	2023
6	Fabric phase sorptive extraction combined with high performance liquid chromatography for the determination of favipiravir in human plasma and breast milk. ⁶²	Tiris G...Locatelli M	36395627	2023
7	Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. ⁶²	Zhang Y...Giovannucci E	36453265	2022
8	Re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36: Let's Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice. ⁶²	Gomez Rivas J...Montorsi F	36405303	2022
9	Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. ⁶²	Chiong E...Davis ID	35134266	2022
10	Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men. ⁶²	Jackson MD...Tulloch-Reid MK	35900615	2022
11	Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer? ⁶²	Sassi H...Rouleau E	36153247	2022
12	Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. ⁶²	Alongi P...Russo G	32543166	2022
13	Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer. ⁶²	Diao Y...Liu J	35171081	2022
14	Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors. ⁶²	Yazgan SC...Urun Y	35899494	2022
15	Chemokines and cytokines: Axis and allies in prostate cancer pathogenesis. ⁶²	Mughees M...Siddiqui JA	35181473	2022
16	Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). ⁶²	Ma TM...Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators	35934601	2022
17	Microbiota and prostate cancer. ⁶²	Rizzo A...Massari F	34536504	2022
18	Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer: AR-V7 is Rare in Hormone-sensitive Prostate Cancer. ⁶²	Sowalsky AG...Sharp A	36038450	2022
19	Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. ⁶²	Bjartell A...Chowdhury S	36353661	2022
20	Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment. ⁶²	Habeshian TS...Chao CR	36349511	2022
21	Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. ⁶²	Carlsson SV...Mansson M	36334968	2022
22	Correction to: Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. ⁶²		36449389	2022
23	Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. ⁶²	Miyahira AK...Soule HR	36443902	2022
24	Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer. ⁶²	Li H...Xu H	36088181	2022
25	Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank. ⁶²	Green HD...Bailey SER	35978138	2022
26	Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort. ⁶²	Khan S...Bensen JT	35880605	2022
27	The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. ⁶²	Emmett L...Hofman MS	35301240	2022
28	The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. ⁶²	Zattoni F...Gandaglia G	36082555	2022
29	Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. ⁶²	De Man K...Schelfhout V	35411446	2022
30	A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand. ⁶²	Morote J...Trilla E	36291883	2022
31	Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes-ready for prime time? ⁶²	Friedrich NA...Csizmadi I	36261588	2022
32	Development and Analytical Validation of a 6-Plex Reverse Transcription Droplet Digital PCR Assay for the Absolute Quantification of Prostate Cancer Biomarkers in Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer. ⁶²	Zavridou M...Lianidou E	36093578	2022
33	Ga-68 Prostate-Specific Membrane Antigen PET/CT: Imaging and Clinical Perspective in Prostate Cancer: Imaging and Clinical Perspective in Prostate Cancer. ⁶²	Puranik AD...Dev ID	36229103	2022
34	Re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. ⁶²	Bosas P...Characiejus D	35907665	2022
35	Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re: Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic Monitoring in Prostate Cancer Should Involve a Cotinine Test in Current Smokers: Smoking Cessation Remains a Cornerstone in Preventive Health Care Overall and for Men with Prostate Cancer. ⁶²	Jochems SHJ...Stocks T	35907663	2022
36	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. ⁶²	Chu CE...Carroll PR	33483265	2022
37	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. ⁶²	Fossati N...EAU Section of Oncological Urology (ESOU) Board	33249083	2022
38	Comparing the clinical performance and cost efficacy of [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis. ⁶²	Alberts I...Afshar-Oromieh A	34773473	2022
39	A Combinatorial Neural Network Analysis Reveals a Synergistic Behaviour of Multiparametric Magnetic Resonance and Prostate Health Index in the Identification of Clinically Significant Prostate Cancer. ⁶²	Gentile F...Terracciano D	35610113	2022
40	Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era? ⁶²	Heetman JG...van den Bergh RCN	36046616	2022
41	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. ⁶²	Gafita A...Benz MR	35767071	2022
42	De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy. ⁶²	Ma B...Li L	35971165	2022
43	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. ⁶²	Lenis AT...Calais J	32958451	2022
44	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. ⁶²	Koshkin VS...McKay R	34363009	2022
45	Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. ⁶²	Wenzel M...Karakiewicz PI	34334344	2022
46	Disparities in germline testing among racial minorities with prostate cancer. ⁶²	Weise N...McKay RR	34775478	2022
47	Racial disparities in prostate cancer among black men: epidemiology and outcomes. ⁶²	Chowdhury-Paulino IM...Mucci LA	34475523	2022
48	The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity. ⁶²	Chaudhary S...Chao HH	35315585	2022
49	Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. ⁶²	Ussing A...Bandholm T	34489536	2022
50	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. ⁶²	Sheehan B...de Bono JS	34167925	2022